Caricamento...
Upregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathway.
Cisplatin has been the most accepted drug for the treatment of ovarian cancer for almost 40 years. Although the majority of patients with ovarian cancer respond to front-line platinum combination chemotherapy, many patients will develop cisplatin-resistance disease, which is extremely rapid and fata...
Salvato in:
| Autori principali: | , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Public Library of Science (PLoS)
2014-01-01
|
| Serie: | PLoS ONE |
| Accesso online: | http://europepmc.org/articles/PMC4035252?pdf=render |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|